Hence, we hypothesized that if we reduce TYMS levels, we would sensitize tumor cells to respond to lower doses of pemetrexed or gemcitabine that were otherwise ineffective in the presence of elevated TYMS commonly detected in clinical patient samples. Here, TYMS is linked to neoplasm.